RxDoctor Payments Data

Eduardo Gallegos, MD

Neurology · Apple Valley, CANPI 1548218522

Payments from drug & device makers

$87,416in general payments, 2019–2025

Across 1,124 payments — averaging $77.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33K
  • Acorda Therapeutics, Inc$24K
  • MDD US Operations, LLC$10K
  • SK Life Science, Inc.$2K
  • Biogen$2K
  • UCB, Inc.$2K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$59,00968%
  • Travel & lodging$4,0895%
  • Food & beverage$24,21928%
  • Education$980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)137$33,267
Acorda Therapeutics, Inc50$23,703
MDD US Operations, LLC61$9,817
SK Life Science, Inc.82$1,735
Biogen65$1,629
UCB, Inc.69$1,623
Novartis69$1,479
Amgen(2 entities)64$1,435
Teva Pharmaceuticals USA, Inc.57$1,371
EMD Serono, Inc.32$888
Neurocrine Biosciences, Inc.22$854
Supernus Pharmaceuticals, Inc.66$719
Argenx US, Inc.25$597
Livanova USA, Inc.6$593
Sunovion Pharmaceuticals Inc.31$531
AstraZeneca19$527
Vanda Pharmaceuticals Inc.19$467
Lundbeck LLC18$455
Eisai Inc.16$371
Acadia Pharmaceuticals Inc17$365
Mallinckrodt Hospital Products Inc.11$333
Kyowa Kirin, Inc.12$316
Amneal Pharmaceuticals LLC14$313
Biohaven Pharmaceutical Holding Company Ltd.8$283
Johnson & Johnson(2 entities)8$274
Lilly USA, LLC9$259
Sanofi8$258
Pfizer8$253
Bristol Myers Squibb13$248
Neurelis, Inc.9$231
Otsuka America Pharmaceutical, Inc.11$229
Biohaven Pharmaceuticals, Inc.11$226
E.r. Squibb & Sons, L.L.C.3$156
Avanir Pharmaceuticals, Inc.9$149
Tanabe Pharma America, Inc.6$143
ANI Pharmaceuticals, Inc.5$143
Genentech USA, Inc.6$140
Takeda Pharmaceuticals U.S.A., Inc.8$140
Gilead1$122
Upsher-smith Laboratories LLC5$93
Banner Life Sciences, LLC3$74
Grifols USA, LLC3$67
GE HealthCare2$57
Adamas Pharmaceuticals, Inc.3$55
Sarepta Therapeutics, Inc.2$46
Mallinckrodt Enterprises LLC2$42
CSL Behring2$40
Scilex Pharmaceuticals Inc.2$35
Immedica Pharma US, Inc.1$35
Jazz Pharmaceuticals Inc.1$33
TG Therapeutics, Inc.1$28
Sumitomo Pharma America, Inc.1$26
Amylyx Pharmaceuticals, Inc.1$21
Alnylam Pharmaceuticals Inc.1$19
Axsome Therapeutics, Inc.1$17
Aucta Pharmaceuticals, Inc.1$17
Arbor Pharmaceuticals, Inc.1$16
W. L. Gore & Associates, Inc.1$15
Adlon Therapeutics L.p.1$14
Impel Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,416 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$57,992
Medicare patients
209
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate28$191,707
AustedoDeutetrabenazine15$185,853
AmpyraDalfampridine16$115,143
AubagioTeriflunomide11$99,808
IngrezzaValbenazine Tosylate11$84,718
FingolimodFingolimod Hcl21$74,851
GlatopaGlatiramer Acetate11$66,101
UbrelvyUbrogepant45$64,964
XcopriCenobamate33$41,944
Oxtellar XrOxcarbazepine46$29,134
QuliptaAtogepant16$19,050
NamzaricMemantine Hcl/Donepezil Hcl21$16,468
Aimovig AutoinjectorErenumab-Aooe20$14,683
Rasagiline Mesylate96$12,558
Memantine Hcl800$11,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$1,371$377,56043 claims
Acorda Therapeutics, IncAmpyra$23,703$115,14316 claims
AbbVieUbrelvy, Qulipta, Namzaric$33,267$100,48282 claims
SanofiAubagio$258$99,80811 claims
Neurocrine Biosciences, Inc.Ingrezza$854$84,71811 claims
SK Life Science, Inc.Xcopri$1,735$41,94433 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$719$29,13446 claims
Upsher-smith Laboratories LLCTopiramate$93$2,265225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →